Edmond DE Rothschild Holding S.A. Has $19.62 Million Stake in QIAGEN N.V. $QGEN

Key Points

• Edmond DE Rothschild Holding S.A. reduced its stake in Qiagen N.V. by 6.4% during the first quarter, now owning 490,970 shares valued at approximately $19.62 million.
• Other institutional investors, such as Wellington Management and Deutsche Bank, significantly increased their holdings in Qiagen, indicating strong market interest with 70% of the stock currently owned by institutional investors.
• Analysts have mixed ratings for Qiagen, with target prices ranging from $48.00 to $55.00, reflecting a generally cautious outlook despite a recent earnings report that met consensus estimates.

Edmond DE Rothschild Holding S.A. lowered its stake in shares of QIAGEN N.V. (NYSE:QGEN - Free Report) by 6.4% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 490,970 shares of the company's stock after selling 33,386 shares during the quarter. Edmond DE Rothschild Holding S.A. owned 0.22% of QIAGEN worth $19,618,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. SVB Wealth LLC bought a new stake in QIAGEN during the 1st quarter worth approximately $31,000. ANTIPODES PARTNERS Ltd bought a new position in shares of QIAGEN in the 1st quarter worth about $94,000. Tower Research Capital LLC TRC increased its stake in QIAGEN by 770.6% during the 4th quarter. Tower Research Capital LLC TRC now owns 2,490 shares of the company's stock valued at $111,000 after purchasing an additional 2,204 shares in the last quarter. GAMMA Investing LLC boosted its holdings in shares of QIAGEN by 93.9% during the 1st quarter. GAMMA Investing LLC now owns 2,943 shares of the company's stock valued at $118,000 after acquiring an additional 1,425 shares during the last quarter. Finally, Federated Hermes Inc. purchased a new position in shares of QIAGEN in the first quarter worth approximately $150,000. 70.00% of the stock is currently owned by hedge funds and other institutional investors.

QIAGEN Stock Performance

Shares of QIAGEN stock traded down $0.55 on Tuesday, reaching $47.03. 532,361 shares of the company were exchanged, compared to its average volume of 1,384,888. The company's 50-day moving average is $48.65 and its two-hundred day moving average is $44.48. The company has a debt-to-equity ratio of 0.25, a quick ratio of 1.35 and a current ratio of 1.61. The firm has a market cap of $10.45 billion, a price-to-earnings ratio of 27.77, a P/E/G ratio of 2.51 and a beta of 0.64. QIAGEN N.V. has a 1-year low of $37.63 and a 1-year high of $51.88.

QIAGEN (NYSE:QGEN - Get Free Report) last released its quarterly earnings data on Tuesday, August 5th. The company reported $0.60 earnings per share for the quarter, hitting the consensus estimate of $0.60. QIAGEN had a return on equity of 14.77% and a net margin of 18.30%.The business had revenue of $533.54 million during the quarter, compared to analyst estimates of $523.97 million. During the same period last year, the company posted $0.55 EPS. The company's revenue was up 7.7% compared to the same quarter last year. QIAGEN has set its Q3 2025 guidance at 0.580- EPS. FY 2025 guidance at 2.350-2.350 EPS. As a group, research analysts expect that QIAGEN N.V. will post 2.26 earnings per share for the current fiscal year.

Analyst Ratings Changes

QGEN has been the subject of a number of recent analyst reports. Wall Street Zen lowered shares of QIAGEN from a "strong-buy" rating to a "buy" rating in a research note on Monday, August 11th. Barclays initiated coverage on QIAGEN in a research report on Tuesday, June 24th. They issued an "overweight" rating and a $55.00 target price on the stock. Cowen reiterated a "hold" rating on shares of QIAGEN in a research report on Thursday, August 7th. Bank of America increased their price objective on QIAGEN from $50.00 to $53.00 and gave the company a "buy" rating in a research note on Thursday, June 26th. Finally, UBS Group raised their target price on QIAGEN from $48.00 to $50.00 and gave the company a "neutral" rating in a report on Thursday, August 7th. Three investment analysts have rated the stock with a Buy rating and eight have assigned a Hold rating to the stock. Based on data from MarketBeat, QIAGEN has a consensus rating of "Hold" and a consensus target price of $49.69.

QIAGEN Company Profile

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.